WHAT IS CLAIMED IS:

1. An oral dosage composition comprising:

(a) a compound that is (-)-halofenate, or (-)-halofenic acid or a pharmaceutically acceptable salt thereof, substantially free from the corresponding (+)-enantiomer; and

(b) febuxostat.

2. The composition of claim 1, where the compound is (-)-halofenate, substantially free from the corresponding (+)-enantiomer.

3. The composition of claim 1, where the compound is (-)-halofenic acid or a pharmaceutically acceptable salt thereof, substantially free from the corresponding (+)-enantiomer.

4. The composition of any one of claims 1 to 3 where the amounts of the compound and of the febuxostat together are effective for once/day dosing.

5. The composition of any one of claims 1 to 4 where the amount of the compound is between 10 mg and 1000 mg.

6. The composition of claim 5 where the amount of the compound is between 100 mg and 800 mg.

7. The composition of any one of claims 1 to 6 where the amount of the febuxostat is between 20 mg and 120 mg.

8. The composition of claim 7 where the amount of the febuxostat is between 40 mg and 120 mg.

9. The composition of any one of claims 1 to 8 that is a tablet.

10. The composition of any one of claims 1 to 8 that is a capsule.

11. The composition of any one of claims 1 to 8 that is a syrup.

12. The composition of any one of claims 1 to 8 that is a suspension.

13. The use of a compound that is (-)-halofenate, or (-)-halofenic acid or a pharmaceutically acceptable salt thereof, substantially free from the corresponding (+)-enantiomer, in the manufacture of a medicament for treating hyperuricemia, or for lowering serum uric acid, or for reducing the size or number of tophi, or for treating urate crystal formation, in a subject with gout, where the subject is also administered febuxostat.

14. The use of claim 13, where the compound is (-)-halofenate, substantially free from the corresponding (+)-enantiomer.

15. The use of claim 13, where the compound is (-)-halofenic acid or a pharmaceutically acceptable salt thereof, substantially free from the corresponding (+)-enantiomer.

16. The use of any one of claims 13 to 15 where the amounts of the compound and of the febuxostat together are effective for once/day dosing.

17. The use of any one of claims 13 to 16 where the compound is administered at between 10 mg/day and 1000 mg/day.

18. The use of claim 17 where the compound is administered at between 100 mg/day and 800 mg/day.

19. The use of any one of claims 13 to 18 where the febuxostat is administered at between 20 mg/day and 120 mg/day.

20. The use of claim 19 where the febuxostat is administered at between 40 mg/day and 120 mg/day.

21. The use of any one of claims 13 to 20, where the subject is refractory to febuxostat.

22. The use of any one of claims 13 to 21 where the subject reaches a serum uric acid level of 6.0 mg/dL or less on administration of the compound and the febuxostat.

23. The use of claim 22 where the subject reaches a serum uric acid level of 5.0 mg/dL or less on administration of the compound and the febuxostat.

24. The use of claim 23 where the subject reaches a serum uric acid level of 4.0 mg/dL or less on administration of the compound and the febuxostat.

25. The use of claim 24 where the subject reaches a serum uric acid level of 3.0 mg/dL or less on administration of the compound and the febuxostat.

26. The use of any one of claims 13 to 25, where the gout is severe gout.

27. The use of any one of claims 13 to 25, where the gout is refractory gout.

28. The use of any one of claims 13 to 27 that is for treating hyperuricemia in a subject with gout.

29. The use of any one of claims 13 to 27 that is for lowering serum uric acid in a subject with gout.

30. The use of any one of claims 13 to 27 that is for reducing the size or number of tophi in a subject with gout.

31. The use of any one of claims 13 to 27 that is for treating urate crystal formation in a subject with gout.

WHAT IS CLAIMED IS

1. An oral dosage composition comprising:

(a) a compound that is ( ) halofenate, or ( ) halofenic acid or a pharmaceutically acceptable salt thereof; and

(b) febuxostat.

2. The composition of claim 1, where the compound is ( ) halofenate.

3. The composition of claim 1, where the compound is ( ) halofenic acid or a pharmaceutically acceptable salt thereof.

4. The composition of any one of claims 1 to 3 where the amount of the compound is between 10 mg and 1000 mg.

5. The composition of claim 4 where the amount of the compound is between 100 mg and 800 mg.

6. The composition of any one of claims 1 to 5 where the amount of the febuxostat is between 20 mg and 120 mg.

7. The composition of claim 6 where the amount of the febuxostat is between 40 mg and 120 mg.

8. The composition of any one of claims 1 to 7 that is a tablet.

9. The composition of any one of claims 1 to 7 that is a capsule.

10. The composition of any one of claims 1 to 7 that is a syrup.

11. The composition of any one of claims 1 to 7 that is a suspension.

12. The composition of any one of claims 1 to 11 for use as a medicament.

13. The composition of any one of claims 1 to 11 for use in the treatment of hyperuricemia.

14. The composition of any one of claims 1 to 11 for use in the treatment of gout.

15. The composition of claim 14 for use in the treatment of severe gout.

16. The composition of claim 14 for use in the treatment of refractory gout.

17. The composition of claim 14 for use in the treatment of tophaceous gout.